抑制微生物负荷以减少危重症肺炎:SMURF可行性 pilot 研究
该研究为前瞻性、单中心、非随机可行性 pilot 研究,设序贯对照期与干预期,纳入≥19岁、预计ICU停留>48小时的成人混合内-外科ICU患者。干预期为每48小时一次鼻内aPDT直至出ICU,对照期为标准ICU治疗不做鼻腔去定植。共分析227例(对照126例、干预101例),招募达标,鼻拭子采集依从性97.7%,干预期57.8%的预定aPDT治疗完整实施、12.0%部分实施,未观察到干预相关严重不良事件。探索性分析显示干预组早期累积鼻腔病原负荷显著降低(p<0.01);裁定VAP/HAP发生率为干预期9.0/1000 ICU患者日 vs 对照期14.9/1000 ICU患者日(发生率比0.61,95%CI 0.31–1.17,未达统计学显著)。作者结论为实施可行且安全,初步支持推进以临床终点为效能目标的多中心随机试验。
要点
- 研究纳入≥19岁、预计ICU停留>48小时的成人混合内-外科ICU患者,干预为每48小时鼻内aPDT直至出ICU。
- 可行性指标:招募目标达成,鼻拭子采集依从性97.7%,干预期57.8%的预定aPDT治疗完整实施、12.0%部分实施。
- 安全性:未观察到干预相关严重不良事件。
- 探索性结果:干预组早期累积鼻腔病原负荷显著降低(p<0.01);裁定VAP/HAP发生率为干预期9.0/1000 ICU患者日 vs 对照期14.9/1000 ICU患者日,发生率比0.61(95%CI 0.31–1.17),未达统计学显著。
- 复合终点(肺炎、微生物清除、累积病原负荷)win ratio为1.29(95%CI 0.74–2.31),倾向于治疗组。
适用人群与场景
- 成人混合内-外科ICU患者,年龄≥19岁,预计ICU停留时间>48小时。
- 研究在三级学术医院的成人混合内-外科ICU进行。
诊断标准与关键阈值
- 肺炎事件裁定采用盲法、基于规则的 criteria,与CDC/NHSN定义一致。
处置流程与药物剂量
- 干预期患者接受鼻内aPDT,每48小时一次,直至ICU出院。
- 对照期患者接受标准ICU治疗,不做鼻腔去定植。
- 鼻拭子在ICU入科时及之后每4天采集一次。
研究设计与关键结果
- 研究类型:前瞻性、单中心、非随机可行性 pilot 研究,设序贯对照期和干预期。
- 样本量:共分析227例患者(对照期126例,干预期101例)。
- 主要可行性终点:招募目标达成;鼻拭子采集依从性97.7%;干预期57.8%的预定aPDT治疗完整实施,12.0%部分实施;未观察到干预相关严重不良事件;肺炎裁定完成且系统间一致性高、缺失数据极少。
- 探索性分析:干预组早期累积鼻腔病原负荷显著低于对照组(p<0.01)。
- 裁定VAP/HAP发生率:干预期9.0/1000 ICU患者日 vs 对照期14.9/1000 ICU患者日,发生率比0.61(95%CI 0.31–1.17),未达统计学显著。
- 分层复合终点(包括肺炎、微生物清除和累积病原负荷)win ratio为1.29(95%CI 0.74–2.31),倾向于治疗组。
证据类型、等级与局限
- 证据类型:前瞻性、单中心、非随机可行性 pilot 研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在ICU实施鼻内aPDT可行且安全,鼻拭子采集依从性高,盲法裁定成功。
- 作者认为,探索性信号显示病原负荷降低和肺炎发生率降低(但未达统计学显著),为推进以临床终点为效能目标的多中心随机试验提供了初步支持。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Nasal antimicrobial photodynamic therapy (aPDT) is a non-antibiotic decolonization strategy with potential to reduce ICU-acquired infections without contributing to antimicrobial resistance. We conducted a feasibility pilot to evaluate implementation of intranasal aPDT in critically ill adults and to generate preliminary estimates of microbiologic and clinical outcomes to inform a future definitive trial. DESIGN: Prospective, single-center, non-randomized feasibility pilot study with sequential control and intervention phases. SETTING: Adult mixed medical–surgical intensive care units at a tertiary academic hospital. PATIENTS: Adults ≥ 19 years with an expected ICU stay > 48 h. INTERVENTION: During the intervention phase, patients received intranasal aPDT every 48 h until ICU discharge. Control-phase patients received standard ICU care without nasal decolonization. Nasal swabs were obtained at ICU admission and every four days. MAIN FEASIBILITY OUTCOMES: Recruitment rate, protocol adherence, safety, data completeness, and ability to adjudicate pneumonia events using blinded, rule-based criteria aligned with CDC/NHSN definitions. RESULTS: A total of 227 patients were analyzed (126 control, 101 intervention). Recruitment targets were met. Adherence to scheduled nasal swab collection was 97.7%. During the intervention phase, 57.8% of scheduled aPDT treatments were delivered in full and 12.0% partially delivered. No intervention-related serious adverse events were observed. Pneumonia adjudication was completed with high inter-system concordance and minimal missing data, supporting adequacy of data capture tools. Exploratory analyses demonstrated significantly lower early cumulative nasal pathogen burden in the intervention group (p < 0.01). The incidence of adjudicated VAP/HAP was 9.0 per 1,000 ICU patient-days during the intervention phase compared with 14.9 per 1,000 ICU patient-days during the control phase (incidence rate ratio 0.61, 95% CI 0.31–1.17, a difference that was not statistically significant). A hierarchical composite endpoint incorporating pneumonia, microbiologic clearance, and cumulative pathogen burden yielded a win ratio of 1.29 (95% CI 0.74–2.31) favoring treatment. CONCLUSIONS: Implementation of nasal aPDT in the ICU was feasible and safe, with high sampling adherence and successful blinded adjudication. Exploratory signals of reduced pathogen burden and lower though not statistically significant, pneumonia incidence provide preliminary support for progression to a multicenter randomized trial powered for clinical endpoints. TRIAL REGISTRATION: NCT06867458 clinicaltrials.gov, Registration date March 6, 2025.
参考来源
- Rohrs E, Ornowska M, Wittmann J, et al. Suppression of microbial burden to reduce pneumonia in critical illness: the SMURF feasibility pilot study. Crit Care. 2026. PMID: 41947247. doi:10.1186/s13054-026-06008-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。